News | August 02, 2021
Ajanta Pharma aims to file 10-12 ANDAs per annum
India business is growing as per projections; whereas US business will bounce back soon.
India business is growing as per projections; whereas US business will bounce back soon.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
The company has already embarked upon significant expansion in Turkey
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
The first batch will be shipped to the Gamaleya Center for the quality control
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Subscribe To Our Newsletter & Stay Updated
